Madison Vaccines Incorporated’s clinical trial for metastatic prostate cancer is expanding to the University of Washington, its third site, the company announced recently.

According to a release, MVI-118 is being explored for use in combination with androgen deprivation therapy to delay resistance and prolong duration of disease control in men with metastatic prostate cancer. Read the full story here.